Evaluate the Safety and Efficacy of 48-Hour Infusions of HNO (Nitroxyl) Donor in Hospitalized Patients With Heart Failure
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 329 participants.
Also called NCT03016325
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 329 participants
- Sponsor
- Registry
-
NCT03016325 -
2016-001685-29
-
- Other papers using this trial's data
- Effects of a Novel Nitroxyl Donor in Acute Heart Failure: The STAND-UP AHF Study
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Canada, Czechia, France, Germany, Greece, Italy, Japan, Netherlands, Poland, Spain, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT03016325. Randomized; quadruple masking; primary purpose treatment. Start 2017-01-13 (actual); primary completion 2019-06-23 (actual). Results posted on 2020-08-19.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Evaluate the Safety and Efficacy of 48-Hour Infusions of HNO (Nitroxyl) Donor in Hospitalized Patients With Heart Failure
- Acronym
- STANDUP AHF
- Condition
- Heart Failure
- Intervention (Drug)
- HNO Donor
- Intervention (Drug)
- Placebo
- Lead sponsor
- Bristol-Myers Squibb
Record details
- Record id
cardio:ct-nct03016325- Content hash
fbde69ebdb3cea1151f68fcbfab9f3ea74c07016ef8b2ffece4c0655555239df